These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 18980972)
21. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing. Nuytten M; Beke L; Van Eynde A; Ceulemans H; Beullens M; Van Hummelen P; Fuks F; Bollen M Oncogene; 2008 Feb; 27(10):1449-60. PubMed ID: 17724462 [TBL] [Abstract][Full Text] [Related]
22. RAS oncogenic signal upregulates EZH2 in pancreatic cancer. Fujii S; Fukamachi K; Tsuda H; Ito K; Ito Y; Ochiai A Biochem Biophys Res Commun; 2012 Jan; 417(3):1074-9. PubMed ID: 22222375 [TBL] [Abstract][Full Text] [Related]
23. EZH2 depletion blocks the proliferation of colon cancer cells. Fussbroich B; Wagener N; Macher-Goeppinger S; Benner A; Fälth M; Sültmann H; Holzer A; Hoppe-Seyler K; Hoppe-Seyler F PLoS One; 2011; 6(7):e21651. PubMed ID: 21765901 [TBL] [Abstract][Full Text] [Related]
25. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells. Sakurai T; Bilim VN; Ugolkov AV; Yuuki K; Tsukigi M; Motoyama T; Tomita Y Biochem Biophys Res Commun; 2012 Jun; 422(4):607-14. PubMed ID: 22609199 [TBL] [Abstract][Full Text] [Related]
26. Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer. Sun Y; Ren D; Zhou Y; Shen J; Wu H; Jin X Cell Death Dis; 2021 Sep; 12(10):878. PubMed ID: 34564701 [TBL] [Abstract][Full Text] [Related]
27. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Wagener N; Holland D; Bulkescher J; Crnković-Mertens I; Hoppe-Seyler K; Zentgraf H; Pritsch M; Buse S; Pfitzenmaier J; Haferkamp A; Hohenfellner M; Hoppe-Seyler F Int J Cancer; 2008 Oct; 123(7):1545-50. PubMed ID: 18623083 [TBL] [Abstract][Full Text] [Related]
28. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Gonzalez ME; DuPrie ML; Krueger H; Merajver SD; Ventura AC; Toy KA; Kleer CG Cancer Res; 2011 Mar; 71(6):2360-70. PubMed ID: 21406404 [TBL] [Abstract][Full Text] [Related]
29. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660 [TBL] [Abstract][Full Text] [Related]
30. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer. Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318 [TBL] [Abstract][Full Text] [Related]
31. EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Guo J; Cai J; Yu L; Tang H; Chen C; Wang Z Cancer Sci; 2011 Mar; 102(3):530-9. PubMed ID: 21205084 [TBL] [Abstract][Full Text] [Related]
32. Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer. Ishikawa S; Hayashi H; Kinoshita K; Abe M; Kuroki H; Tokunaga R; Tomiyasu S; Tanaka H; Sugita H; Arita T; Yagi Y; Watanabe M; Hirota M; Baba H Int J Cancer; 2014 Dec; 135(11):2528-36. PubMed ID: 24346863 [TBL] [Abstract][Full Text] [Related]
33. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874 [TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer. Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951 [TBL] [Abstract][Full Text] [Related]
35. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Yan J; Ng SB; Tay JL; Lin B; Koh TL; Tan J; Selvarajan V; Liu SC; Bi C; Wang S; Choo SN; Shimizu N; Huang G; Yu Q; Chng WJ Blood; 2013 May; 121(22):4512-20. PubMed ID: 23529930 [TBL] [Abstract][Full Text] [Related]
36. EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines. Zhang YB; Niu HT; Chang JW; Dong GL; Ma XB Eur J Cancer Care (Engl); 2011 Jan; 20(1):106-12. PubMed ID: 20148941 [TBL] [Abstract][Full Text] [Related]
37. Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu. Zhang Y; Liu G; Lin C; Liao G; Tang B Life Sci; 2013 May; 92(17-19):896-902. PubMed ID: 23562851 [TBL] [Abstract][Full Text] [Related]
38. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810 [TBL] [Abstract][Full Text] [Related]
39. Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells. Bai J; Ma M; Cai M; Xu F; Chen J; Wang G; Shuai X; Tao K Cell Prolif; 2014 Jun; 47(3):211-8. PubMed ID: 24738879 [TBL] [Abstract][Full Text] [Related]
40. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Bao B; Ali S; Banerjee S; Wang Z; Logna F; Azmi AS; Kong D; Ahmad A; Li Y; Padhye S; Sarkar FH Cancer Res; 2012 Jan; 72(1):335-45. PubMed ID: 22108826 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]